Article
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine.
The New England journal of medicine - 19 Nov 2015
Neafsey D E, Juraska M, Bedford T, Benkeser D, Valim C, Griggs A, Lievens M, Abdulla S, Adjei S, Agbenyega T, Agnandji S T, Aide P, Anderson S, Ansong D, Aponte J J, Asante K P, Bejon P, Birkett A J, Bruls M, Connolly K M, D'Alessandro U, Dobaño C, Gesase S, Greenwood B, Grimsby J, Tinto H, Hamel M J, Hoffman I, Kamthunzi P, Kariuki S, Kremsner P G, Leach A, Lell B, Lennon N J, Lusingu J, Marsh K, Martinson F, Molel J T, Moss E L, Njuguna P, Ockenhouse C F, Ogutu B Ragama, Otieno W, Otieno L, Otieno K, Owusu-Agyei S, Park D J, Pellé K, Robbins D, Russ C, Ryan E M, Sacarlal J, Sogoloff B, Sorgho H, Tanner M, Theander T, Valea I, Volkman S K, Yu Q, Lapierre D, Birren B W, Gilbert P B, Wirth D F
Abstract excerpt
BACKGROUND: The RTS,S/AS01 vaccine targets the circumsporozoite protein of Plasmodium falciparum and has partial protective efficacy against clinical and severe malaria disease in infants and children. We investigated whether the vaccine efficacy was specific to certain parasite genotypes at the circumsporozoite protein locus. METHODS: We used polymerase chain reaction-based next-generation sequencing of DNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.